A novel spliceosome inhibitor triggers anti-tumor CD4⁺ and CD8⁺ T cell responses in murine models of pediatric-relevant cancer.
6 affiliations
- 1Université Paris-Saclay, INSERM UMR1015, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
- 2Université Paris-Saclay, CNRS, BioCIS, 91400 Orsay, France.
- 3Université Paris Cité, INSERM U1342, Institut de Recherche Saint-Louis (IRSL), Paris, France.
- 4SABNP, Université Evry, INSERM U1204, Université Paris-Saclay, 91025 Evry, France.
- 5Gustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
- 6Université Paris-Saclay, Gustave Roussy, INSERM UMR1363, Biothérapies Innovantes, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
Abstract
Immunotherapy has been proved to have a high potential to change the outcomes of patients with advanced cancer. However, the efficacy of immune checkpoint inhibitors in most classical pediatric cancers remains limited, underscoring the need for other novel immunomodulatory strategies, such as small-molecule agents, either synthetically derived or isolated from natural sources, which can modulate intracellular immune pathways. Among these, spliceosome inhibitors have emerged as a promising class of compounds capable of reshaping the tumor antigenic landscape. We developed a new generation of spliceosome-targeting molecules that interfere with mRNA processing, enhance major histocompatibility complex class I (MHC-I) and MHC-II expression in tumor cell, and potentiate T cell-mediated immune responses. The new splicing inhibitor BL828 inhibited spliceosome function, upregulated surface MHC-I and MHC-II expression, and induced hallmarks associated with immunogenic cell death in vitro. In neuroblastoma-bearing mice, BL828 treatment significantly delayed tumor growth in an immune-dependent manner, modulated the tumor microenvironment with enhanced activation of antigen-presenting cells, and promoted a robust CD8⁺ T cell and CD4⁺ cytotoxic-like T cell response against murine pediatric neuroblastoma cancers. These findings support splicing inhibition as a strategy to enhance antigen presentation and anti-tumor immunity in murine models of pediatric-relevant cancers, supporting further evaluation of BL828 as a therapeutic candidate.
Related
- Aggregated Low-Density Lipoprotein (agLDL) Triggers Inflammatory Responses in Macrophages through Toll-Like Receptor 4 (TLR4)
- Case Report: Diverse clinical phenotypes and treatment responses in pediatric autoimmune nodopathy: a case series
- U2AF2 as a regulatory hub in cancer: linking spliceosome dysregulation, metabolic reprogramming, and non-coding RNA networks to targeted therapy
- Characterizing How Families Cope with Pediatric Misophonia: Youth Coping, Parent Responses, and Associations with Symptom Severity
- Pediatric and adult primary human airway epithelia exhibit similar rhinovirus C replication, innate responses, and expression of protein receptor
BibTeX
@article{demeules2026novel,
title = {{A novel spliceosome inhibitor triggers anti-tumor CD4⁺ and CD8⁺ T cell responses in murine models of pediatric-relevant cancer.}},
author = {Mélanie Demeules and Boris Letribot and Lisa Giraldo and Congcong Li and Alexandre Maucuer and Birgit Geoerger and Mouad Alami and Sébastien Apcher},
journal = {Molecular therapy. Oncology},
year = {2026},
month = sep,
doi = {10.1016/j.omton.2026.201355},
url = {https://europepmc.org/article/MED/42926841},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - A novel spliceosome inhibitor triggers anti-tumor CD4⁺ and CD8⁺ T cell responses in murine models of pediatric-relevant cancer.
AU - Mélanie Demeules
AU - Boris Letribot
AU - Lisa Giraldo
AU - Congcong Li
AU - Alexandre Maucuer
AU - Birgit Geoerger
AU - Mouad Alami
AU - Sébastien Apcher
PY - 2026
DA - 2026/09/30
JO - Molecular therapy. Oncology
DO - 10.1016/j.omton.2026.201355
UR - https://europepmc.org/article/MED/42926841
AB - Immunotherapy has been proved to have a high potential to change the outcomes of patients with advanced cancer. However, the efficacy of immune checkpoint inhibitors in most classical pediatric cancers remains limited, underscoring the need for other novel immunomodulatory strategies, such as small-molecule agents, either synthetically derived or isolated from natural sources, which can modulate intracellular immune pathways. Among these, spliceosome inhibitors have emerged as a promising class of compounds capable of reshaping the tumor antigenic landscape. We developed a new generation of spliceosome-targeting molecules that interfere with mRNA processing, enhance major histocompatibility complex class I (MHC-I) and MHC-II expression in tumor cell, and potentiate T cell-mediated immune responses. The new splicing inhibitor BL828 inhibited spliceosome function, upregulated surface MHC-I and MHC-II expression, and induced hallmarks associated with immunogenic cell death in vitro. In neuroblastoma-bearing mice, BL828 treatment significantly delayed tumor growth in an immune-dependent manner, modulated the tumor microenvironment with enhanced activation of antigen-presenting cells, and promoted a robust CD8⁺ T cell and CD4⁺ cytotoxic-like T cell response against murine pediatric neuroblastoma cancers. These findings support splicing inhibition as a strategy to enhance antigen presentation and anti-tumor immunity in murine models of pediatric-relevant cancers, supporting further evaluation of BL828 as a therapeutic candidate.
SN - 2950-3299
ER -